Testing rimegepant for migraine—time to revise the trial design? – Authors' reply

Robert Croop; Peter J. Goadsby; David A. Stock; Richard B. Lipton

doi:10.1016/S0140-6736(20)30231-2

Testing rimegepant for migraine—time to revise the trial design? – Authors' reply

Robert Croop, Peter J. Goadsby, David A. Stock, Richard B. Lipton

Neurology

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	1901-1902
Number of pages	2
Journal	The Lancet
Volume	395
Issue number	10241
DOIs	https://doi.org/10.1016/S0140-6736(20)30231-2
State	Published - Jun 20 2020

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1016/S0140-6736(20)30231-2

Cite this

@article{bdd3dbca2aff47aa91c144228f9556da,

title = "Testing rimegepant for migraine—time to revise the trial design? – Authors' reply",

author = "Robert Croop and Goadsby, {Peter J.} and Stock, {David A.} and Lipton, {Richard B.}",

note = "Funding Information: RC is employed by and holds stock options and stock in Biohaven Pharmaceuticals and has a patent related to the use of rimegepant pending. PJG reports personal fees for consulting from Biohaven Pharmaceuticals during writing; grants and personal fees from Amgen and Eli Lilly; grants from Celgene; personal fees from Alder Biopharmaceuticals, Allergan, Clexio, Electrocore LLC, eNeura, Impel Neuropharma, MundiPharma, Novartis, Teva Pharmaceuticals, and WL Gore; fees for publishing from Oxford University Press, Massachusetts Medical Society, Wolters Kluwer, and MedicoLegal work; fees for advice through Gerson Lehrman Group and Guidepoint; holds stock options in Trigemina, outside of writing; and a patent for magnetic stimulation for headache assigned to eNeura without fee. DAS is an employee and shareholder of Biohaven Pharmaceuticals. RBL reports personal fees from Acorda Therapeutics, Alder, Allergan, Amgen, Avanir Pharmaceuticals, Biohaven, CVS Health, Dr Reddy's Laboratories, Eli Lilly and Company, eNeura Therapeutics, Merck, Novartis, Sun Pharmaceutical Industries, Supernus Pharmaceuticals, Teva Pharmaceuticals USA, Vector psychometrics, Vedanta Research, outside of writing; receives royalties from Wolff's Headache seventh and eighth edition (Oxford Press University, 2009); and consults for and holds stock options in Biohaven Pharmaceuticals and eNeura.",

year = "2020",

month = jun,

day = "20",

doi = "10.1016/S0140-6736(20)30231-2",

language = "English (US)",

volume = "395",

pages = "1901--1902",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "10241",

}

TY - JOUR

T1 - Testing rimegepant for migraine—time to revise the trial design? – Authors' reply

AU - Croop, Robert

AU - Goadsby, Peter J.

AU - Stock, David A.

AU - Lipton, Richard B.

N1 - Funding Information: RC is employed by and holds stock options and stock in Biohaven Pharmaceuticals and has a patent related to the use of rimegepant pending. PJG reports personal fees for consulting from Biohaven Pharmaceuticals during writing; grants and personal fees from Amgen and Eli Lilly; grants from Celgene; personal fees from Alder Biopharmaceuticals, Allergan, Clexio, Electrocore LLC, eNeura, Impel Neuropharma, MundiPharma, Novartis, Teva Pharmaceuticals, and WL Gore; fees for publishing from Oxford University Press, Massachusetts Medical Society, Wolters Kluwer, and MedicoLegal work; fees for advice through Gerson Lehrman Group and Guidepoint; holds stock options in Trigemina, outside of writing; and a patent for magnetic stimulation for headache assigned to eNeura without fee. DAS is an employee and shareholder of Biohaven Pharmaceuticals. RBL reports personal fees from Acorda Therapeutics, Alder, Allergan, Amgen, Avanir Pharmaceuticals, Biohaven, CVS Health, Dr Reddy's Laboratories, Eli Lilly and Company, eNeura Therapeutics, Merck, Novartis, Sun Pharmaceutical Industries, Supernus Pharmaceuticals, Teva Pharmaceuticals USA, Vector psychometrics, Vedanta Research, outside of writing; receives royalties from Wolff's Headache seventh and eighth edition (Oxford Press University, 2009); and consults for and holds stock options in Biohaven Pharmaceuticals and eNeura.

PY - 2020/6/20

Y1 - 2020/6/20

UR - http://www.scopus.com/inward/record.url?scp=85086518617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85086518617&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(20)30231-2

DO - 10.1016/S0140-6736(20)30231-2

M3 - Letter

C2 - 32563365

AN - SCOPUS:85086518617

SN - 0140-6736

VL - 395

SP - 1901

EP - 1902

JO - The Lancet

JF - The Lancet

IS - 10241

ER -

Testing rimegepant for migraine—time to revise the trial design? – Authors' reply

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this